Progenics to host industry conference call

Kathy Mahdoubi | | Health Imaging | Molecular Imaging

Progenics Pharmaceuticals, a producer of oncologic drugs, most notably a prostate-specific membrane antigen (PSMA) targeted therapy currently in clinical trials, has announced that the company will be hosting a conference call to review second quarter 2014 financials and other topics on Friday, Aug. 8, at 8:30 a.m. ET.

Progenics has a pipeline of drugs currently in phase II clinical trials, including its PSMA-targeted immunotherapy (PSMA ADC) for patients with castration-resistant prostate cancer and a radiotherapy called an “ultra-orphan radiotherapy candidate.”

Also in Progenics’ potential offerings is a novel imaging agent Tc-99m MIP-1404 currently in a SPECT study and phase II trial and sponsored by Cambridge, Mass., based Molecular Insight Pharmaceuticals, which Progenics announced it was acquiring in January 2013.

The company based in Tarrytown, N.Y., will be webcasting the conference call. Stakeholders will have the opportunity to replay the call for two weeks following the live event.

Progenics reported a net loss of $9.3 million for the first quarter of 2014, which was an improvement over the $11.3 million loss announced for the first quarter last year.
 

Kathy Mahdoubi

Related Content

Researchers receive grant worth millions to develop portable PET scanner
Why is the US still dependent on foreign medical isotope production?
Downed high-flux reactor could restart sooner than anticipated
Some nuc med departments are already feeling the strain of the isotope shortage
NorthStar opens facility to assist with development and distribution of vital radioisotopes
Lizard saliva could be key to spotting elusive pancreatic tumors

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.